Department of Radiation Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
Department of Radiation Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
Clin Oncol (R Coll Radiol). 2024 May;36(5):278-286. doi: 10.1016/j.clon.2024.02.003. Epub 2024 Feb 10.
To evaluate the incidence and pattern of contralateral nodal relapse (CLNR), contralateral nodal relapse-free survival (CLNRFS) and risk factors predicting CLNR in well-lateralised oral cavity cancers (OCC) treated with unilateral surgery and adjuvant ipsilateral radiotherapy with or without concurrent chemotherapy.
Consecutive patients of well-lateralised OCC treated between 2012 and 2017 were included. The primary endpoint was incidence of CLNR and CLNRFS. Univariable and multivariable analyses were carried out to identify potential factors predicting CLNR.
Of the 208 eligible patients, 21 (10%) developed isolated CLNR at a median follow-up of 45 months. The incidence of CLNR was 21.3% in node-positive patients. CLNR was most common at level IB (61.9%) followed by level II. The 5-year CLNRFS and overall survival were 82.5% and 57.7%, respectively. Any positive ipsilateral lymph node (P = 0.001), two or more positive lymph nodes (P < 0.001), involvement of ipsilateral level IB (P = 0.002) or level II lymph node (P < 0.001), presence of extranodal extension (P < 0.001), lymphatic invasion (P = 0.015) and perineural invasion (P = 0.021) were significant factors for CLNR on univariable analysis. The presence of two or more positive lymph nodes (P < 0.001) was an independent prognostic factor for CLNR on multivariable analysis. CLNR increased significantly with each increasing lymph node number beyond two compared with node-negative patients.
The overall incidence of isolated CLNR is low in well-lateralised OCC. Patients with two or more positive lymph nodes have a higher risk of CLNR and may be considered for elective treatment of contralateral neck.
评估单侧手术和辅助同侧放疗(伴或不伴同期化疗)治疗的单侧化口腔癌(OCC)患者对侧淋巴结复发(CLNR)的发生率和模式、对侧淋巴结无复发生存(CLNRFS)和预测 CLNR 的危险因素。
纳入 2012 年至 2017 年间连续治疗的单侧化 OCC 患者。主要终点为 CLNR 的发生率和 CLNRFS。进行单变量和多变量分析以确定预测 CLNR 的潜在因素。
208 例符合条件的患者中,21 例(10%)在中位随访 45 个月时出现孤立性 CLNR。CLNR 的发生率在阳性淋巴结患者中为 21.3%。CLNR 最常见于 IB 级(61.9%),其次是 II 级。5 年 CLNRFS 和总生存率分别为 82.5%和 57.7%。任何同侧阳性淋巴结(P = 0.001)、两个或更多阳性淋巴结(P < 0.001)、同侧 IB 级(P = 0.002)或 II 级淋巴结受累(P < 0.001)、存在结外扩展(P < 0.001)、淋巴血管侵犯(P = 0.015)和神经周围侵犯(P = 0.021)是单变量分析中 CLNR 的显著因素。多变量分析中,两个或更多阳性淋巴结(P < 0.001)是 CLNR 的独立预后因素。与阴性淋巴结患者相比,超过两个阳性淋巴结的患者 CLNR 发生率显著增加。
在单侧化 OCC 中,孤立性 CLNR 的总体发生率较低。有两个或更多阳性淋巴结的患者发生 CLNR 的风险较高,可能需要考虑对侧颈部选择性治疗。